Biohaven Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BHVN in the last 30 days.
See all $BHVN insider activity →Biohaven (BHVN) shares fell 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the impact of the opakalim deal. The company received $400M in cash, extending its runway through 2028. Trading volume was 175% of average.
Biohaven (BHVN) announced a licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 ion channel platform and opakalim. The company also won a $4M damages ruling in a lawsuit. Biohaven's stock surged 16% for the week, according to S&P Global Market Intelligence.
Biohaven Pharmaceutical (BHVN) shares fell 2.4% to $14.03 after announcing a $795M licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, including epilepsy candidate opakalim. Investors sold shares, removing a key catalyst from Biohaven's pipeline. A recent Bank of America downgrade also weighed on sentiment, citing concerns about the epilepsy data and cash runway. The broader market had little impact on the stock's movement.
Over the past 7 days, alphai's AI scored 11 news stories mentioning BHVN (Biohaven Ltd.). Coverage has skewed bullish: 9 bullish, 0 neutral, and 2 bearish.
Recent BHVN coverage spans corporate actions, mergers & acquisitions and financial news.
Target reduction and cash‑in deal shift valuation focus to pipeline, likely pressuring the stock further.
The deal provides substantial upfront cash and future royalty upside, while the legal win removes a liability.
The deal removes Biohaven's lead epilepsy candidate, reducing near‑term catalyst value and prompting a sell‑the‑news reaction.
Deal provides immediate cash infusion and long‑term royalty stream, supporting Biohaven's valuation.
Significant non‑dilutive capital strengthens balance sheet and reduces burn, likely supporting upside in Biohaven's share price.
alphai scores every news story that mentions BHVN with an AI model for sentiment and relevance, and aggregates insider trades from Biohaven Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biohaven (BHVN) shares fell 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the impact of the opakalim deal. The company received $400M in cash, extending its runway through 2028. Trading volume was 175% of average.
2 min readBiohaven (BHVN) announced a licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 ion channel platform and opakalim. The company also won a $4M damages ruling in a lawsuit. Biohaven's stock surged 16% for the week, according to S&P Global Market Intelligence.
2 min readBiohaven Pharmaceutical (BHVN) shares fell 2.4% to $14.03 after announcing a $795M licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, including epilepsy candidate opakalim. Investors sold shares, removing a key catalyst from Biohaven's pipeline. A recent Bank of America downgrade also weighed on sentiment, citing concerns about the epilepsy data and cash runway. The broader market had little impact on the stock's movement.
2 min readBiohaven Ltd. (BHVN) shares rose 7% after announcing a global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform and epilepsy treatment candidate opakalim. The deal includes up to $795 million in payments and royalties. Opakalim is in Phase 2/3 trials, with results expected in late 2026. SK Biopharmaceuticals will handle future program costs and assume commercial responsibilities.
2 min readBiohaven Ltd. (BHVN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy ● SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 mi
2 min readBiohaven (BHVN) and SK Biopharmaceuticals agreed on a global licensing deal for Biohaven's Kv7 ion channel platform, led by opakalim, a Phase 2/3 epilepsy treatment. SK Biopharmaceuticals will pay up to $795M in milestones and royalties, with $400M in near-term cash to Biohaven. The deal strengthens Biohaven's balance sheet and extends its runway for pipeline development.
3 min readSK Biopharmaceuticals has signed a global licensing deal with Biohaven Bioscience Ireland for epilepsy drug Opakalim and related compounds. The agreement includes a $400 million upfront payment, with potential total value of $795 million, plus royalties on net sales. Biohaven will receive $350 million at closing and $50 million after one year.
2 min readBiohaven (BHVN) said it signed a clinical supply agreement with Regeneron (REGN) to test BHV-1530 with Regeneron’s cemiplimab (Libtayo) in solid tumors. The article also cites Regeneron Q2 2026 results: $4.3B revenue (+17% YoY), GAAP net income $1.29B, and Biohaven Q2 2026 net loss $137.3M.
6 min readBiohaven Ltd. (BHVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results • First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial und
6 min readBiohaven Ltd. (BHVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a dire
2 min read
